Lupin receives tentative U S FDA approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Glenmark is the first company in the world to launch Remogliflozin (100 mg) + Vildagliptin (50 mg) Fixed Dose Combination (FDC) at an affordable price for adults with type 2 diabetes in India.Glenmark Pharmaceuticals has launched a fixed dose combination of its novel, patent protected and globally researched sodium glucose co-transporter inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes.
The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo V and Remozen V.
European Commission approves Roche s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
F. Hoffmann-La Roche Ltd: European Commission approves Roche s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
1,2,3
administered under the skin in just minutes compared to hours with intravenous (
IV) infusion of Perjeta plus Herceptin
4,5,6
Approval is based on results from the pivotal phase III FeDeriCa trial, which showed that Phesgo delivered
non-inferior
7
Basel, 23 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo
, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.
F. Hoffmann-La Roche Ltd
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs
1,2,3
administered under the skin in just minutes compared to hours with intravenous (
IV) infusion of Perjeta plus Herceptin
4,5,6
Approval is based on results from the pivotal phase III FeDeriCa trial, which showed that Phesgo delivered